To read the full story, subscribe or sign in.

China pharma migration: Hengrui greenlighted for Hong Kong IPO

April 28, 2025

Jiangsu Hengrui Pharmaceuticals Co. Ltd. is the latest mainland China pharmaceutical company to seek a capital raise on the Hong Kong stock exchange, winning clearance April 28 from the China Securities Regulatory Commission to float new H-shares.

BioWorld Analysis and data insight Financings Regulatory Cancer Cardiovascular Immune Immuno-oncology IPO Asia-Pacific FDA NMPA

Today's news in brief

BioWorld

BioWorld briefs for July 23, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

Tree in the shape of human head losing leaves

KBN-2201 reverses key features of Alzheimer’s in mice

BioWorld Science

Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.

Click chemistry drug bound to pancreatic cancer cells from mice

In vivo click ADCs could address tumor heterogeneity

BioWorld

Researchers at Washington University in St. Louis have used click chemistry to link a second antibody to a pre-existing antibody-drug conjugate (ADC) in vivo. In...